Results 121 to 130 of about 152,178 (350)

First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811

Future Oncology, 2020
Treatment options for patients with HER2-positive advanced gastric cancer are limited, and the prognosis for these patients is poor. Pembrolizumab has demonstrated promising antitumor activity in patients with advanced gastric or gastroesophageal ...
H. Chung, Y. Bang, Charles S Fuchs, S. Qin, T. Satoh, K. Shitara, J. Tabernero, E. Cutsem, M. Alsina, Z. Cao, Jia Lu, P. Bhagia, C. Shih, Y. Janjigian   +13 more
semanticscholar   +1 more source

Development of tCAP(N3): Affinity Peptide‐Aided, pH‐Triggered Strategy for Site‐Specific Native IgG Modification

Chemistry – A European Journal, EarlyView.
The tCAP(N3) reagent, featuring a stable and self‐activating precursor, enables site‐specific conjugation of native IgGs. This Fc‐affinity peptide approach selectively transfers an Ac‐Lys(N3)‐Gly‐Gly payload to Lys248, producing divalently azidated antibody while preserving its biological function.
Hiroko Kawakami, Abdur Rafique, Shugo Tsuda, Asaki Nagashima, Yukie Nohara, Naoki Dozono, Ken Sakamoto, Shun Masuda, Masato Kiyoshi, Hiroko Shibata, Akiko Ishii‐Watabe, Taku Yoshiya, Yuji Ito   +12 more
wiley   +1 more source

Assessment of safety and tolerability of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: Results of an open-label, randomized, multicenter, phase IIIB ESCAPE trial

Cancer Treatment and Research Communications
Aim: To assess the safety and tolerability of subcutaneous (SC) trastuzumab (Herceptin) administered either with a single-use injection device (SID) or manually from a vial using a hand-held syringe.
Dilyara Kaidarova, Edvard Zhavrid, Oxana Shatkovskaya, Aliaksandr Prokharau, Nina Akhmed, Dauren Sembayev, Zhanna Rutzhanova, Alexandr Ivankov   +7 more
doaj   +1 more source

Optimizing Body Size‐Based Dosing Approaches for Antibody–Drug Conjugates

Clinical Pharmacology &Therapeutics, EarlyView.
Optimized dosing precision of antibody–drug conjugates (ADCs) remains challenging due to narrow therapeutic indices, efficacious doses near the maximum tolerated dose, and substantial interindividual variability in exposure. Body size‐based dosing can reduce exposure variability when the allometric scaling exponent for clearance α = 1 but may over‐ or ...
Andrew B. SyBing, Diane D. Wang
wiley   +1 more source

Cannabinoid receptor CB2 drives HER2 pro-oncogenic signaling in breast cancer [PDF]

, 2015
Pharmacological activation of cannabinoid receptors elicits antitumoral responses in different models of cancer. However, the biological role of these receptors in tumor physio-pathology is still unknown.
Alkatout, Ibrahim, Andradas, Clara, Arnold, Norbert, Artola, Marta, Bauer, Maret, Blasco-Benito, Sandra, Bronsert, Peter, Caffarel, María M., Canela, Enric I., Fernández-Piqueras, José, Flores, Juana M., García-Taboada, Elena, Guzmán, Manuel, Hamann, Sigrid, Klapper, Wolfram, Martín-Villar, Ester, McCormick, Peter J., Megías, Diego, Moreno, Estefanía, Moreno-Bueno, Gema, Ortega-Gutiérrez, Silvia, Pérez-Gómez, Eduardo, Pérez-Martínez, Manuel, Quintanilla, Miguel, Röcken, Christoph, Soriano, Joaquim, Staebler, Annette, Stickeler, Elmar, Sánchez, Cristina, Villa-Morales, María, Vázquez-Villa, Henar, Wenners, Antonia   +31 more
core   +1 more source

Dapagliflozin alleviates high‐fat‐induced obesity cardiomyopathy by inhibiting ferroptosis

ESC Heart Failure, Volume 12, Issue 2, Page 1358-1373, April 2025.
Abstract Aim: Dapagliflozin (Dapa) is a novel hypoglycaemic agent with multiple cardiovascular protective effects, and it is widely used in treatment of heart failure patients, but whether it can improve obese phenotype of heart failure and its mechanism is still unclear.
Di Chen, Jiahao Shi, Yue Wu, Lizhu Miao, Zilin Wang, Yixuan Wang, Siwei Xu, Yu Lou   +7 more
wiley   +1 more source

Circulating neuregulin-1 and galectin-3 can be prognostic markers in breast cancer [PDF]

, 2017
Background: It is important to identify novel plasmatic biomarkers that can contribute to assessing the prognosis and outcome of breast cancer patients.
Cardelli, Patrizia, DE IULIIS, Francesca, Lanza, Rosina, Salerno, Gerardo, Scarpa, Susanna, Taglieri, Ludovica   +5 more
core   +1 more source

Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer

British Journal of Cancer, 2019
The HER2-targeted antibody–drug conjugate trastuzumab emtansine (T-DM1) is approved for the treatment of metastatic, HER2-positive breast cancer after prior trastuzumab and taxane therapy, and has also demonstrated efficacy in the adjuvant setting in ...
F. Hunter, H. R. Barker, B. Lipert, F. Rothé, G. Gebhart, M. Piccart-Gebhart, C. Sotiriou, S. Jamieson   +7 more
semanticscholar   +1 more source

Chinese pan‐cancer patient genomic characteristics: A comprehensive analysis based on the National Cancer Center–Clinical Diagnostics Knowledgebase real‐world clinical sequencing cohort

Interdisciplinary Medicine, EarlyView.
We assembled National Cancer Center–Clinical Diagnostics Knowledgebase, a clinical genomic knowledgebase of 6935 tumors with matched normal samples, revealing key somatic alterations and actionable variants (70.2% of the cohort). Enrichment of certain different gene mutations was observed between Chinese and American populations, along with a strong ...
Hongrui Li, Shun Wang, Guowei Zhao, Jiangtao Li, Xin Li, Bingning Wang, Yi Zhang, Mengfei Yao, Lei Guo, Jianming Ying, Wenbin Li   +10 more
wiley   +1 more source

A Non-Covalent Antibody Complex for the Delivery of anti-cancer drugs [PDF]

, 2019
Antibody drug conjugates (ADCs), which are obtained by coupling a potent cytotoxic agent to a monoclonal antibody (mAb), are traditionally bound in a random way to lysine or cysteine residues, with the final product's heterogeneity having an important ...
Grigoletto, Antonella, Maso, Katia, Monia Montagner, Isabella, Pasut, Gianfranco, Rosato, Antonio, Schiavon, Oddone   +5 more
core   +1 more source